Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 476Carcinoma, Non-Small-Cell Lung 233Breast Neoplasms 196Ovarian Neoplasms 171Glioblastoma 157Carcinoma, Hepatocellular 131Neoplasms 128Rectal Neoplasms 114Colonic Neoplasms 110Neoplasm Metastasis 106Brain Neoplasms 98Lung Neoplasms 96Fallopian Tube Neoplasms 85Carcinoma, Renal Cell 77Glioma 69Pancreatic Neoplasms 54Liver Neoplasms 44Melanoma 43Gliosarcoma 43Uterine Cervical Neoplasms 40Adenocarcinoma of Lung 39Stomach Neoplasms 37Recurrence 33Astrocytoma 30Carcinoma, Ovarian Epithelial 28Endometrial Neoplasms 27Triple Negative Breast Neoplasms 26Kidney Neoplasms 23Prostatic Neoplasms 22Esophageal Neoplasms 21

Interventions

Folfox protocol 2Bevacizumab 2pembrolizumab 1IFL protocol 1HMPL-013 1Drug Therapy 1Control Groups 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unresectable Metastatic Colorectal Cancer × Bevacizumab × Clear all
NCT06642844 2024-10-15

PHARBEVACOL

University Hospital, Tours

Phase 3 Not yet recruiting
244 enrolled
Gastrointestinal

Unresectable Metastatic Colorectal Cancer

NCT05068206 2021-10-20

A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Unknown
120 enrolled
Gastrointestinal

Unresectable Metastatic Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡